ClinicalTrials.gg
Not yet recruitingNCT05112263TOCASUUpdated Mar 29, 2023

Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis

An interventional study of Tofacitinib and Cyclosporine in Ulcerative Colitis, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing tofacitinib in Colitis, Ulcerative — 3 open to participants now, 6 under way, 1 of them phase 3. tofacitinib · Colitis, Ulcerative.

Planned enrollment
8th of 14
96 · median 107
Started
2023
the only one that year
No phase
Only one
of the 14
Registered
10th of 14
by date
Lead sponsor
2 of 14
Post Graduate Institute of Medical Education and Research, Chandigarh

Among the 14 studies testing tofacitinib in Colitis, Ulcerative, this one is the 8th largest by planned enrollment, is the only one that started in 2023, is the only one with no phase, and was the 10th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 14 studies testing tofacitinib in Colitis, Ulcerative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tofacitinib in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This randomised trial plans to compare oral tofacitinib with intravenous cyclosporine in patients with acute severe ulcerative colitis who have failed to respond to intravenous steroids

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients admitted with Acute severe ulcerative colitis as defined by Modified Truelove and Witts Criteria WITH Failure to respond to intravenous (Hydrocortisone 100 mg IV QID OR IV Methylprednisolone 60 mg IV OD) as defined by

  • Day 3 non-response as per Oxford criteria (stool frequency of > 8/day, OR stool frequency between 3-8 with CRP > 45 mg/L PLUS
  • Ongoing activity as defined by Partial Mayo Score of > 3 (rectal bleeding sub-score of >1)
  • Decision to start therapy (within 5-7 days of starting intravenous steroids)

Exclusion criteria

Exclusion Criteria:

  • Age \<18, Age > 65 years

    • E1 disease (involvement distal to rectosigmoid junction only)
    • Crohn's disease
    • to intravenous cyclosporine or oral tofacitinib

      • Renal failure, uncontrolled hypertension, seizure disorder,and uncorrected hypomagnesemia (\<1.5 mg/L)
      • Previous thrombosis, or prothrombotic state, on oral , history of herpes zoster, active TB, active hepatitis, past opportunistic infections, h/o diverticulitis, Age >50 plus at least one cardiac risk factor
    • Patient wants treatment with intravenous infliximab or wants surgery
    • Underlying sepsis or active infection (Enteric infections, Clostridium difficile, active or C, Tuberculosis, zoster, CMV disease)
    • Toxic megacolon, previous dysplasia or any indication of immediate surgery
    • Known
    • Pregnancy or Lactation
    • Unwilling to provide consent or for follow-up
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Active comparator
    Group A

    Group A: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks

    Drug: Cyclosporine

  • Experimental
    Group B

    Oral Tofacitinib 10 mg TDS for 3 days, and then 10 mg BD to complete 8 weeks followed by 5 mg BD till follow-up (14 weeks)

    Drug: Tofacitinib

Interventions

  • For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study

  • : Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight

06

What researchers measure

Primary outcomes

  1. Treatment failure

    I) At Day 7 Absence of clinical response at day 7 (as defined by Partial Mayo of \> 3) II) By Day 98 1. Relapse (Partial Mayo Score of 3 or more) between day 7 and day 98 requiring additional therapy 2. Absence of steroid free remission at 14 weeks (Mayo \< 2 with MES 1 or less) 3. Need for colectomy, third line medical rescue or biologics or mortality 4. Serious adverse effect needing interruption of treatment

    Time frame: 14 weeks

Secondary outcomes

  1. Clinical response

    Partial Mayo \<4

    Time frame: 7 days

  2. Absence of steroid free remission

    Mayo score of more than 2 with endoscopic sub-score of more than 1

    Time frame: day 98

  3. Colectomy free survival

    No need for colectomy

    Time frame: 98 days

  4. Time to clinical response

    Partial Mayo of 3 or less

    Time frame: 98 days

  5. Endoscopic healing

    Mayo endoscopic sub-score of 1 or less

    Time frame: Day 98

  6. Serious adverse effects

    requiring hospitalization, cessation of treatment and events like cardiovascular events, pulmonary embolism, venous thrombosis, any infection, malignancy, gastrointestinal perforation

    Time frame: 98 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — The anonymised participant data may be shared on reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Dec 2025, 29 months later.

Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 29 months is below that.

Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Nov 8, 2021
StartEst.
Jul 1, 2023
Primary completionEst.
Dec 1, 2025
CompletionEst.
Jun 1, 2026
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05112263
Responsible party
Vishal Sharma (Associate Professor, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Nov 8, 2021
Start date
Jul 1, 2023 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Mar 29, 2023

Study contacts

Vishal Sharma
Contact
docvishalsharma@gmail.com
+917087008099
Vishal Sharma
principal investigator · PGIMER Chandigarh
Vineet Ahuja
principal investigator · AIIMS Delhi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion